Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment
Locoregional therapy and multi-kinase inhibitor agent have been the backbone of treatment for hepatocellular carcinoma (HCC) patients. However, the effect of combination or sequential use of locoregional therapy on HCC patients receiving multi-kinase inhibitor remain uncertain. Therefore, we aim to...
Saved in:
| Published in | Journal of the Formosan Medical Association Vol. 123; no. 7; pp. 788 - 795 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Singapore
Elsevier B.V
01.07.2024
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0929-6646 1876-0821 |
| DOI | 10.1016/j.jfma.2024.01.031 |
Cover
| Abstract | Locoregional therapy and multi-kinase inhibitor agent have been the backbone of treatment for hepatocellular carcinoma (HCC) patients. However, the effect of combination or sequential use of locoregional therapy on HCC patients receiving multi-kinase inhibitor remain uncertain. Therefore, we aim to explore whether the subsequent locoregional therapy provides better survival in HCC patients under lenvatinib treatment.
From March 2018 to April 2020, a total of 78 unresectable HCC patients receiving lenvatinib were recruited. Image response was evaluated by dynamic image using the modified RECIST criteria. Among patients with tumor progression under lenvatinib treatment, whether receiving subsequent locoregional therapy or not were documented. Overall survival between two groups and the predictors for tumor progression were also analyzed.
Among the 78 patients receiving lenvatinib, the median age was 67.8 years old, and 69.2 % were male. Forty-four patients (56.4 %) experienced tumor progression with time to progression 5.1 months (95 % confidence interval (CI): 4.7–6.8) months. In multivariable Cox regression analysis, albumin-bilirubin (ALBI) grade II (adjusted HR: 2.883, P = 0.0104), and treatment duration less than three months (adjusted HR: 3.801, P = 0.0014) were the independent predictive factors for tumor progression, while patients achieving objective response under lenvatinib treatment within 12 weeks was the independent protective factor for tumor progression (adjusted HR: 0.144, P = 0.0020). Among the 44 patients with tumor progression, twenty-six (59.1 %) patients received subsequent locoregional therapy after tumor progression. Comparing to those with tumor progression without locoregional treatment, patients who received subsequent locoregional therapy had significantly better survival (1st year cumulative survival rate 70 % vs 27 %, log-rank P = 0.003).
ALBI grade, treatment duration of lenvatinib, and achieving objective image response within twelve weeks were the independent predictive factors for tumor progression. Furthermore, longer overall survival was observed in tumor progression patients with subsequent locoregional therapy and with better liver preserved function. |
|---|---|
| AbstractList | Locoregional therapy and multi-kinase inhibitor agent have been the backbone of treatment for hepatocellular carcinoma (HCC) patients. However, the effect of combination or sequential use of locoregional therapy on HCC patients receiving multi-kinase inhibitor remain uncertain. Therefore, we aim to explore whether the subsequent locoregional therapy provides better survival in HCC patients under lenvatinib treatment.
From March 2018 to April 2020, a total of 78 unresectable HCC patients receiving lenvatinib were recruited. Image response was evaluated by dynamic image using the modified RECIST criteria. Among patients with tumor progression under lenvatinib treatment, whether receiving subsequent locoregional therapy or not were documented. Overall survival between two groups and the predictors for tumor progression were also analyzed.
Among the 78 patients receiving lenvatinib, the median age was 67.8 years old, and 69.2 % were male. Forty-four patients (56.4 %) experienced tumor progression with time to progression 5.1 months (95 % confidence interval (CI): 4.7–6.8) months. In multivariable Cox regression analysis, albumin-bilirubin (ALBI) grade II (adjusted HR: 2.883, P = 0.0104), and treatment duration less than three months (adjusted HR: 3.801, P = 0.0014) were the independent predictive factors for tumor progression, while patients achieving objective response under lenvatinib treatment within 12 weeks was the independent protective factor for tumor progression (adjusted HR: 0.144, P = 0.0020). Among the 44 patients with tumor progression, twenty-six (59.1 %) patients received subsequent locoregional therapy after tumor progression. Comparing to those with tumor progression without locoregional treatment, patients who received subsequent locoregional therapy had significantly better survival (1st year cumulative survival rate 70 % vs 27 %, log-rank P = 0.003).
ALBI grade, treatment duration of lenvatinib, and achieving objective image response within twelve weeks were the independent predictive factors for tumor progression. Furthermore, longer overall survival was observed in tumor progression patients with subsequent locoregional therapy and with better liver preserved function. Background: Locoregional therapy and multi-kinase inhibitor agent have been the backbone of treatment for hepatocellular carcinoma (HCC) patients. However, the effect of combination or sequential use of locoregional therapy on HCC patients receiving multi-kinase inhibitor remain uncertain. Therefore, we aim to explore whether the subsequent locoregional therapy provides better survival in HCC patients under lenvatinib treatment. Methods: From March 2018 to April 2020, a total of 78 unresectable HCC patients receiving lenvatinib were recruited. Image response was evaluated by dynamic image using the modified RECIST criteria. Among patients with tumor progression under lenvatinib treatment, whether receiving subsequent locoregional therapy or not were documented. Overall survival between two groups and the predictors for tumor progression were also analyzed. Results: Among the 78 patients receiving lenvatinib, the median age was 67.8 years old, and 69.2 % were male. Forty-four patients (56.4 %) experienced tumor progression with time to progression 5.1 months (95 % confidence interval (CI): 4.7–6.8) months. In multivariable Cox regression analysis, albumin-bilirubin (ALBI) grade II (adjusted HR: 2.883, P = 0.0104), and treatment duration less than three months (adjusted HR: 3.801, P = 0.0014) were the independent predictive factors for tumor progression, while patients achieving objective response under lenvatinib treatment within 12 weeks was the independent protective factor for tumor progression (adjusted HR: 0.144, P = 0.0020). Among the 44 patients with tumor progression, twenty-six (59.1 %) patients received subsequent locoregional therapy after tumor progression. Comparing to those with tumor progression without locoregional treatment, patients who received subsequent locoregional therapy had significantly better survival (1st year cumulative survival rate 70 % vs 27 %, log-rank P = 0.003). Conclusion: ALBI grade, treatment duration of lenvatinib, and achieving objective image response within twelve weeks were the independent predictive factors for tumor progression. Furthermore, longer overall survival was observed in tumor progression patients with subsequent locoregional therapy and with better liver preserved function. Locoregional therapy and multi-kinase inhibitor agent have been the backbone of treatment for hepatocellular carcinoma (HCC) patients. However, the effect of combination or sequential use of locoregional therapy on HCC patients receiving multi-kinase inhibitor remain uncertain. Therefore, we aim to explore whether the subsequent locoregional therapy provides better survival in HCC patients under lenvatinib treatment.BACKGROUNDLocoregional therapy and multi-kinase inhibitor agent have been the backbone of treatment for hepatocellular carcinoma (HCC) patients. However, the effect of combination or sequential use of locoregional therapy on HCC patients receiving multi-kinase inhibitor remain uncertain. Therefore, we aim to explore whether the subsequent locoregional therapy provides better survival in HCC patients under lenvatinib treatment.From March 2018 to April 2020, a total of 78 unresectable HCC patients receiving lenvatinib were recruited. Image response was evaluated by dynamic image using the modified RECIST criteria. Among patients with tumor progression under lenvatinib treatment, whether receiving subsequent locoregional therapy or not were documented. Overall survival between two groups and the predictors for tumor progression were also analyzed.METHODSFrom March 2018 to April 2020, a total of 78 unresectable HCC patients receiving lenvatinib were recruited. Image response was evaluated by dynamic image using the modified RECIST criteria. Among patients with tumor progression under lenvatinib treatment, whether receiving subsequent locoregional therapy or not were documented. Overall survival between two groups and the predictors for tumor progression were also analyzed.Among the 78 patients receiving lenvatinib, the median age was 67.8 years old, and 69.2 % were male. Forty-four patients (56.4 %) experienced tumor progression with time to progression 5.1 months (95 % confidence interval (CI): 4.7-6.8) months. In multivariable Cox regression analysis, albumin-bilirubin (ALBI) grade II (adjusted HR: 2.883, P = 0.0104), and treatment duration less than three months (adjusted HR: 3.801, P = 0.0014) were the independent predictive factors for tumor progression, while patients achieving objective response under lenvatinib treatment within 12 weeks was the independent protective factor for tumor progression (adjusted HR: 0.144, P = 0.0020). Among the 44 patients with tumor progression, twenty-six (59.1 %) patients received subsequent locoregional therapy after tumor progression. Comparing to those with tumor progression without locoregional treatment, patients who received subsequent locoregional therapy had significantly better survival (1st year cumulative survival rate 70 % vs 27 %, log-rank P = 0.003).RESULTSAmong the 78 patients receiving lenvatinib, the median age was 67.8 years old, and 69.2 % were male. Forty-four patients (56.4 %) experienced tumor progression with time to progression 5.1 months (95 % confidence interval (CI): 4.7-6.8) months. In multivariable Cox regression analysis, albumin-bilirubin (ALBI) grade II (adjusted HR: 2.883, P = 0.0104), and treatment duration less than three months (adjusted HR: 3.801, P = 0.0014) were the independent predictive factors for tumor progression, while patients achieving objective response under lenvatinib treatment within 12 weeks was the independent protective factor for tumor progression (adjusted HR: 0.144, P = 0.0020). Among the 44 patients with tumor progression, twenty-six (59.1 %) patients received subsequent locoregional therapy after tumor progression. Comparing to those with tumor progression without locoregional treatment, patients who received subsequent locoregional therapy had significantly better survival (1st year cumulative survival rate 70 % vs 27 %, log-rank P = 0.003).ALBI grade, treatment duration of lenvatinib, and achieving objective image response within twelve weeks were the independent predictive factors for tumor progression. Furthermore, longer overall survival was observed in tumor progression patients with subsequent locoregional therapy and with better liver preserved function.CONCLUSIONALBI grade, treatment duration of lenvatinib, and achieving objective image response within twelve weeks were the independent predictive factors for tumor progression. Furthermore, longer overall survival was observed in tumor progression patients with subsequent locoregional therapy and with better liver preserved function. |
| Author | Jeng, Wen-Juei Lin, Po-Ting Lin, Chen-Chun Lin, Shi-Ming Teng, Wei Lin, Chun-Yen Sheen, I-Shyan |
| Author_xml | – sequence: 1 givenname: Po-Ting orcidid: 0000-0002-7486-8908 surname: Lin fullname: Lin, Po-Ting email: linpoting0101@gmail.com organization: Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taiwan – sequence: 2 givenname: Wei surname: Teng fullname: Teng, Wei email: b101090023@gmail.com organization: Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taiwan – sequence: 3 givenname: Wen-Juei surname: Jeng fullname: Jeng, Wen-Juei email: Rachel.jeng@gmail.com organization: Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taiwan – sequence: 4 givenname: Chen-Chun surname: Lin fullname: Lin, Chen-Chun email: lincc53@gmail.com organization: Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taiwan – sequence: 5 givenname: Chun-Yen surname: Lin fullname: Lin, Chun-Yen email: chunyenlin@gmail.com organization: Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taiwan – sequence: 6 givenname: Shi-Ming surname: Lin fullname: Lin, Shi-Ming email: lsmpaicyto@gmail.com organization: Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taiwan – sequence: 7 givenname: I-Shyan surname: Sheen fullname: Sheen, I-Shyan email: happy95kevin@gmail.com organization: Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Branch, Taiwan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38310071$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUU1v1DAQtVAR3S78AQ4oRy5ZbMfxJogLqvioVIkDcLYce7J1cOzFTiLtof-dCVt64ACSZY_evDfWvHdFLkIMQMhLRneMMvlm2A39qHeccrGjbEcr9oRsWLOXJW04uyAb2vK2lFLIS3KV80CpkG0rn5HLqqkYpXu2Ifdf5y7DzxnCVPhoYoKDi0H7YrqDpI-n4piij-GQizynxS3YcWEFDwlydgsUd3DUUzTg_ex1KoxOxoU46gJhh2NzMQcLqfAQFkSC64opgZ5G7D0nT3vtM7x4eLfk-8cP364_l7dfPt1cv78tjZDNVOqurynjlW2xAlpzKVtqjRWM4WG6smC6uur7phe6sxVw4JL2bK87BnhXW3JznmujHtQxuVGnk4raqd9ATAel0-SMB2UthUbYGr3qhQTRcs1ZxcAYUWuB5Za8Ps9CE9C3PKnR5XV9HSDOWXE0HQV1vVJfPVDnbgT7-PEf-5HAzwSTYs4J-kcKo2rNWA1qzVitGSvKFGaMondnEaBji4OkskGjDViXwEy4kvu3_O1fcuMxFaP9Dzj9T_wLSCnGXA |
| Cites_doi | 10.1016/j.jhep.2016.01.012 10.1056/NEJMoa0708857 10.1371/journal.pone.0231828 10.1055/s-2007-1007122 10.1159/000502905 10.1002/hep.26328 10.1002/ijc.28362 10.1007/s00262-012-1380-8 10.1200/JCO.20.00808 10.1200/JCO.2014.57.9151 10.1158/0008-5472.CAN-13-1186 10.1016/S1470-2045(15)00050-9 10.1016/S0140-6736(17)31046-2 10.1136/gutjnl-2019-318934 10.1016/j.jhep.2016.10.029 10.1016/j.jhep.2018.04.010 10.21873/anticanres.13710 10.1159/000510299 10.21873/anticanres.13768 10.1186/1471-2407-14-849 10.1159/000452846 10.1016/j.jhep.2018.03.019 10.1016/S1470-2045(18)30937-9 10.1056/NEJMoa1717002 10.7150/jca.19964 10.1038/labinvest.2010.205 10.1016/j.jfma.2020.10.031 10.1158/2326-6066.CIR-14-0076 10.1200/JCO.19.01307 10.1007/s12072-016-9774-x 10.3390/cancers13010160 10.1186/s40792-020-01078-3 10.1016/S0140-6736(18)30207-1 10.1056/NEJMoa1915745 10.1200/JCO.2012.42.9936 10.1002/ijc.31216 10.1159/000501281 10.1016/j.intimp.2017.02.028 10.1016/S2468-1253(17)30156-5 10.1016/j.jhep.2018.11.029 10.1016/j.jhep.2011.03.007 |
| ContentType | Journal Article |
| Copyright | 2024 Formosan Medical Association Copyright © 2024 Formosan Medical Association. Published by Elsevier B.V. All rights reserved. |
| Copyright_xml | – notice: 2024 Formosan Medical Association – notice: Copyright © 2024 Formosan Medical Association. Published by Elsevier B.V. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 DOA |
| DOI | 10.1016/j.jfma.2024.01.031 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1876-0821 |
| EndPage | 795 |
| ExternalDocumentID | oai_doaj_org_article_dd0e84d5046f46e492a2131ecc45a421 38310071 10_1016_j_jfma_2024_01_031 S0929664624000846 |
| Genre | Journal Article |
| GroupedDBID | --- --K .1- .55 .FO .~1 0R~ 188 1B1 1P~ 1~. 1~5 2UF 2WC 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ 8RM AABNK AAEDW AAIKJ AALRI AAQFI AAWTL AAXUO AAYWO ABBQC ABFNM ABJNI ABMAC ABWVN ABXDB ACGFO ACRPL ACVFH ADCNI ADMUD ADNMO ADVLN AEKER AENEX AEUPX AEVXI AEXQZ AFPUW AFRHN AFTJW AGHFR AGYEJ AIGII AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ CS3 DU5 EBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FIRID FNPLU GBLVA GROUPED_DOAJ GX1 HVGLF HZ~ IHE IPNFZ J1W M41 MO0 N9A O-L O9- OK1 OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SDF SDG SEL SES SSZ TR2 UZ5 X7M Z5R ZXP 0SF 6I. AACTN AAFTH AFCTW AINHJ CEFSP CNMHZ NCXOZ AAYXX CITATION NPM 7X8 ~HD |
| ID | FETCH-LOGICAL-c468t-abf50123d9abfe0526690dcd4114111a3decb53ff8f4abd3e2e260f17ab1e17a3 |
| IEDL.DBID | .~1 |
| ISSN | 0929-6646 |
| IngestDate | Wed Aug 27 01:28:57 EDT 2025 Sun Sep 28 05:56:31 EDT 2025 Mon Jul 21 05:57:01 EDT 2025 Tue Jul 01 03:18:48 EDT 2025 Sat Jun 29 15:30:27 EDT 2024 Tue Aug 26 17:12:00 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Systemic therapy Radiofrequency ablation Lenvatinib Survival Transarterial chemoembolization |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2024 Formosan Medical Association. Published by Elsevier B.V. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c468t-abf50123d9abfe0526690dcd4114111a3decb53ff8f4abd3e2e260f17ab1e17a3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-7486-8908 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0929664624000846 |
| PMID | 38310071 |
| PQID | 2929131551 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_dd0e84d5046f46e492a2131ecc45a421 proquest_miscellaneous_2929131551 pubmed_primary_38310071 crossref_primary_10_1016_j_jfma_2024_01_031 elsevier_sciencedirect_doi_10_1016_j_jfma_2024_01_031 elsevier_clinicalkey_doi_10_1016_j_jfma_2024_01_031 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-01 |
| PublicationDateYYYYMMDD | 2024-07-01 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Singapore |
| PublicationPlace_xml | – name: Singapore |
| PublicationTitle | Journal of the Formosan Medical Association |
| PublicationTitleAlternate | J Formos Med Assoc |
| PublicationYear | 2024 |
| Publisher | Elsevier B.V Elsevier |
| Publisher_xml | – name: Elsevier B.V – name: Elsevier |
| References | Lin, Lu, Chen, Jeng, Chen, Hu, Yang (bib3) 2017; 11 Yin, Zhang, Wang, Zhang, Gan, Ge, Chen (bib28) 2014; 14 Sunay, Foote, Leatherman, Edwards, Armstrong, Nirschl, Hicks (bib37) 2017; 46 Kudo (bib24) 2019; 8 Sprinzl, Reisinger, Puschnik, Ringelhan, Ackermann, Hartmann, Schiemann (bib34) 2013; 57 Pan, Mu, Wu, Wu, Xie, Li, Lyu (bib27) 2017; 8 Farsaci, Donahue, Coplin, Grenga, Lepone, Molinolo, Hodge (bib35) 2014; 2 Lin, Teng, Jeng, Lin, Lin, Sheen (bib33) 2020 Gillmore, Stuart, Kirkwood, Hameeduddin, Woodward, Burroughs, Meyer (bib22) 2011; 55 Finn, Ryoo, Merle, Kudo, Bouattour, Lim, Breder (bib6) 2020; 38 Kudo, Finn, Qin, Han, Ikeda, Piscaglia, Baron (bib5) 2018; 391 Lencioni, Llovet, Han, Tak, Yang, Guglielmi, Paik (bib15) 2016; 64 Kudo, Ueshima, Ikeda, Torimura, Tanabe, Aikata, Izumi (bib13) 2020; 69 Duffy, Ulahannan, Makorova-Rusher, Rahma, Wedemeyer, Pratt, Davis (bib17) 2017; 66 Johnson, Berhane, Kagebayashi, Satomura, Teng, Reeves, O'Beirne (bib31) 2015; 33 Zhu, Park, Ryoo, Yen, Poon, Pastorelli, Blanc (bib11) 2015; 16 Finn, Ikeda, Zhu, Sung, Baron, Kudo, Okusaka (bib23) 2020; 38 Llovet, Ricci, Mazzaferro, Hilgard, Gane, Blanc, de Oliveira (bib4) 2008; 359 Chang, Yang, Chiu, Lu, Liao, Liang, Hsu (bib41) 2018; 142 Zhu, Kang, Yen, Finn, Galle, Llovet, Assenat (bib7) 2019; 20 Llovet, Bru, Bruix (bib2) 1999; 19 Villanueva (bib1) 2019; 381 Peng, Zhang, Chen, Xu, Liang, Lin, Guo (bib29) 2013; 31 Hiraoka, Kumada, Atsukawa, Hirooka, Tsuji, Ishikawa, Takaguchi (bib30) 2019; 97 Shao, Wang, Lin (bib20) 2021; 120 Romero, Chaput, Poirier-Colame, Rusakiewicz, Jacquelot, Chaba, Mortier (bib36) 2014; 74 Kirino, Tsuchiya, Kurosaki, Kaneko, Inada, Yamashita, Osawa (bib43) 2020; 15 Chen, Yan, Lu, Chen, Yu, Yang, Cheng (bib38) 2014; 134 Ohya, Hayashida, Tsuji, Kuramoto, Shibata, Setoyama, Hayashi (bib26) 2020; 6 Shimose, Iwamoto, Tanaka, Niizeki, Shirono, Noda, Kamachi (bib19) 2021; 13 Cao, Xu, Youn, Cabrera, Zhang, Gabrilovich, Nelson (bib39) 2011; 91 Sato, Beppu, Kinoshita, Yuki, Suyama, Chiyonaga, Motohara (bib25) 2019; 39 Abou-Alfa, Meyer, Cheng, El-Khoueiry, Rimassa, Ryoo, Cicin (bib12) 2018; 379 Finn, Merle, Granito, Huang, Bodoky, Pracht, Yokosuka (bib10) 2018; 69 El-Khoueiry, Sangro, Yau, Crocenzi, Kudo, Hsu, Kim (bib8) 2017; 389 Kawamura, Kobayashi, Shindoh, Kobayashi, Okubo, Tominaga, Kajiwara (bib18) 2020; 9 Hiraoka, Kumada, Kudo, Hirooka, Tsuji, Itobayashi, Kariyama (bib32) 2017; 6 (bib21) 2018; 69 Park, Kim, Kim, Bae, Paik, Lee, Kim (bib14) 2019; 70 Finn, Qin, Ikeda, Galle, Ducreux, Kim, Kudo (bib9) 2020; 382 Cabrera, Ararat, Xu, Brusko, Wasserfall, Atkinson, Chang (bib40) 2013; 62 Meyer, Fox, Ma, Ross, James, Sturgess, Stubbs (bib16) 2017; 2 Takahashi, Moriguchi, Seko, Ishikawa, Yo, Kimura, Fujii (bib42) 2019; 39 Sato (10.1016/j.jfma.2024.01.031_bib25) 2019; 39 Takahashi (10.1016/j.jfma.2024.01.031_bib42) 2019; 39 Romero (10.1016/j.jfma.2024.01.031_bib36) 2014; 74 Sprinzl (10.1016/j.jfma.2024.01.031_bib34) 2013; 57 Kudo (10.1016/j.jfma.2024.01.031_bib24) 2019; 8 Llovet (10.1016/j.jfma.2024.01.031_bib4) 2008; 359 Hiraoka (10.1016/j.jfma.2024.01.031_bib32) 2017; 6 Kudo (10.1016/j.jfma.2024.01.031_bib13) 2020; 69 Shimose (10.1016/j.jfma.2024.01.031_bib19) 2021; 13 Ohya (10.1016/j.jfma.2024.01.031_bib26) 2020; 6 Lin (10.1016/j.jfma.2024.01.031_bib33) 2020 Pan (10.1016/j.jfma.2024.01.031_bib27) 2017; 8 Meyer (10.1016/j.jfma.2024.01.031_bib16) 2017; 2 Gillmore (10.1016/j.jfma.2024.01.031_bib22) 2011; 55 Finn (10.1016/j.jfma.2024.01.031_bib10) 2018; 69 Llovet (10.1016/j.jfma.2024.01.031_bib2) 1999; 19 Duffy (10.1016/j.jfma.2024.01.031_bib17) 2017; 66 Kawamura (10.1016/j.jfma.2024.01.031_bib18) 2020; 9 Chang (10.1016/j.jfma.2024.01.031_bib41) 2018; 142 Cabrera (10.1016/j.jfma.2024.01.031_bib40) 2013; 62 Finn (10.1016/j.jfma.2024.01.031_bib23) 2020; 38 Kudo (10.1016/j.jfma.2024.01.031_bib5) 2018; 391 Shao (10.1016/j.jfma.2024.01.031_bib20) 2021; 120 Peng (10.1016/j.jfma.2024.01.031_bib29) 2013; 31 Park (10.1016/j.jfma.2024.01.031_bib14) 2019; 70 Johnson (10.1016/j.jfma.2024.01.031_bib31) 2015; 33 Farsaci (10.1016/j.jfma.2024.01.031_bib35) 2014; 2 El-Khoueiry (10.1016/j.jfma.2024.01.031_bib8) 2017; 389 Hiraoka (10.1016/j.jfma.2024.01.031_bib30) 2019; 97 (10.1016/j.jfma.2024.01.031_bib21) 2018; 69 Cao (10.1016/j.jfma.2024.01.031_bib39) 2011; 91 Finn (10.1016/j.jfma.2024.01.031_bib6) 2020; 38 Kirino (10.1016/j.jfma.2024.01.031_bib43) 2020; 15 Finn (10.1016/j.jfma.2024.01.031_bib9) 2020; 382 Chen (10.1016/j.jfma.2024.01.031_bib38) 2014; 134 Yin (10.1016/j.jfma.2024.01.031_bib28) 2014; 14 Lin (10.1016/j.jfma.2024.01.031_bib3) 2017; 11 Zhu (10.1016/j.jfma.2024.01.031_bib11) 2015; 16 Zhu (10.1016/j.jfma.2024.01.031_bib7) 2019; 20 Sunay (10.1016/j.jfma.2024.01.031_bib37) 2017; 46 Abou-Alfa (10.1016/j.jfma.2024.01.031_bib12) 2018; 379 Villanueva (10.1016/j.jfma.2024.01.031_bib1) 2019; 381 Lencioni (10.1016/j.jfma.2024.01.031_bib15) 2016; 64 |
| References_xml | – volume: 11 start-page: 199 year: 2017 end-page: 208 ident: bib3 article-title: HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma publication-title: Hepatol Int – volume: 8 start-page: 3506 year: 2017 end-page: 3513 ident: bib27 article-title: Comparison of combined transcatheter arterial chemoembolization and CT-guided radiofrequency ablation with surgical resection in patients with hepatocellular carcinoma within the up-to-seven criteria: a multicenter case-matched study publication-title: J Cancer – volume: 39 start-page: 5695 year: 2019 end-page: 5701 ident: bib25 article-title: Conversion hepatectomy for huge hepatocellular carcinoma with arterioportal shunt after chemoembolization and lenvatinib therapy publication-title: Anticancer Res – volume: 57 start-page: 2358 year: 2013 end-page: 2368 ident: bib34 article-title: Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells publication-title: Hepatology – volume: 69 start-page: 1492 year: 2020 end-page: 1501 ident: bib13 article-title: Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial publication-title: Gut – volume: 19 start-page: 329 year: 1999 end-page: 338 ident: bib2 article-title: Prognosis of hepatocellular carcinoma: the BCLC staging classification publication-title: Semin Liver Dis – year: 2020 ident: bib33 article-title: Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients publication-title: Eur J Gastroenterol Hepatol – volume: 9 start-page: 756 year: 2020 end-page: 770 ident: bib18 article-title: Lenvatinib-transarterial chemoembolization sequential therapy as an effective treatment at progression during lenvatinib therapy for advanced hepatocellular carcinoma publication-title: Liver Cancer – volume: 74 start-page: 68 year: 2014 end-page: 80 ident: bib36 article-title: Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Ralpha and NKG2D triggering publication-title: Cancer Res – volume: 69 start-page: 182 year: 2018 end-page: 236 ident: bib21 article-title: Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma publication-title: J Hepatol – volume: 134 start-page: 319 year: 2014 end-page: 331 ident: bib38 article-title: Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity publication-title: Int J Cancer – volume: 389 start-page: 2492 year: 2017 end-page: 2502 ident: bib8 article-title: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial publication-title: Lancet – volume: 391 start-page: 1163 year: 2018 end-page: 1173 ident: bib5 article-title: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial publication-title: Lancet – volume: 382 start-page: 1894 year: 2020 end-page: 1905 ident: bib9 article-title: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma publication-title: N Engl J Med – volume: 64 start-page: 1090 year: 2016 end-page: 1098 ident: bib15 article-title: Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial publication-title: J Hepatol – volume: 6 start-page: 318 year: 2020 ident: bib26 article-title: Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy publication-title: Surg Case Rep – volume: 8 start-page: 299 year: 2019 end-page: 311 ident: bib24 article-title: A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE publication-title: Liver Cancer – volume: 15 year: 2020 ident: bib43 article-title: Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma publication-title: PLoS One – volume: 16 start-page: 859 year: 2015 end-page: 870 ident: bib11 article-title: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial publication-title: Lancet Oncol – volume: 55 start-page: 1309 year: 2011 end-page: 1316 ident: bib22 article-title: EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization publication-title: J Hepatol – volume: 39 start-page: 5149 year: 2019 end-page: 5156 ident: bib42 article-title: Impact of relative dose intensity of early-phase lenvatinib treatment on therapeutic response in hepatocellular carcinoma publication-title: Anticancer Res – volume: 20 start-page: 282 year: 2019 end-page: 296 ident: bib7 article-title: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet Oncol – volume: 62 start-page: 737 year: 2013 end-page: 746 ident: bib40 article-title: Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma publication-title: Cancer Immunol Immunother – volume: 33 start-page: 550 year: 2015 end-page: 558 ident: bib31 article-title: Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade publication-title: J Clin Oncol – volume: 38 start-page: 2960 year: 2020 end-page: 2970 ident: bib23 article-title: Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma publication-title: J Clin Oncol – volume: 31 start-page: 426 year: 2013 end-page: 432 ident: bib29 article-title: Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial publication-title: J Clin Oncol – volume: 2 start-page: 1090 year: 2014 end-page: 1102 ident: bib35 article-title: Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines publication-title: Cancer Immunol Res – volume: 379 start-page: 54 year: 2018 end-page: 63 ident: bib12 article-title: Cabozantinib in patients with advanced and progressing hepatocellular carcinoma publication-title: N Engl J Med – volume: 13 year: 2021 ident: bib19 article-title: Alternating lenvatinib and trans-arterial therapy prolongs overall survival in patients with inter-mediate stage HepatoCellular carcinoma: a propensity score matching study publication-title: Cancers – volume: 6 start-page: 204 year: 2017 end-page: 215 ident: bib32 article-title: Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan society of hepatology: a comparison with the liver damage and child-pugh classifications publication-title: Liver Cancer – volume: 381 start-page: e2 year: 2019 ident: bib1 article-title: Hepatocellular carcinoma publication-title: Reply. N Engl J Med – volume: 91 start-page: 598 year: 2011 end-page: 608 ident: bib39 article-title: Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model publication-title: Lab Invest – volume: 38 start-page: 193 year: 2020 end-page: 202 ident: bib6 article-title: Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial publication-title: J Clin Oncol – volume: 2 start-page: 565 year: 2017 end-page: 575 ident: bib16 article-title: Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial publication-title: Lancet Gastroenterol Hepatol – volume: 14 start-page: 849 year: 2014 ident: bib28 article-title: Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma publication-title: BMC Cancer – volume: 66 start-page: 545 year: 2017 end-page: 551 ident: bib17 article-title: Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma publication-title: J Hepatol – volume: 97 start-page: 277 year: 2019 end-page: 285 ident: bib30 article-title: Important clinical factors in sequential therapy including lenvatinib against unresectable hepatocellular carcinoma publication-title: Oncology – volume: 46 start-page: 112 year: 2017 end-page: 123 ident: bib37 article-title: Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo publication-title: Int Immunopharm – volume: 69 start-page: 353 year: 2018 end-page: 358 ident: bib10 article-title: Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial publication-title: J Hepatol – volume: 359 start-page: 378 year: 2008 end-page: 390 ident: bib4 article-title: Sorafenib in advanced hepatocellular carcinoma publication-title: N Engl J Med – volume: 70 start-page: 684 year: 2019 end-page: 691 ident: bib14 article-title: Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial publication-title: J Hepatol – volume: 120 start-page: 1051 year: 2021 end-page: 1060 ident: bib20 article-title: Diagnosis G, systemic therapy G. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the taiwan liver cancer association and the gastroenterological society of Taiwan publication-title: J Formos Med Assoc – volume: 142 start-page: 1878 year: 2018 end-page: 1889 ident: bib41 article-title: Targeting tumor-infiltrating Ly6G(+) myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma publication-title: Int J Cancer – volume: 64 start-page: 1090 year: 2016 ident: 10.1016/j.jfma.2024.01.031_bib15 article-title: Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial publication-title: J Hepatol doi: 10.1016/j.jhep.2016.01.012 – volume: 359 start-page: 378 year: 2008 ident: 10.1016/j.jfma.2024.01.031_bib4 article-title: Sorafenib in advanced hepatocellular carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa0708857 – year: 2020 ident: 10.1016/j.jfma.2024.01.031_bib33 article-title: Combining immune checkpoint inhibitor with lenvatinib prolongs survival than lenvatinib alone in sorafenib-experienced hepatocellular carcinoma patients publication-title: Eur J Gastroenterol Hepatol – volume: 15 year: 2020 ident: 10.1016/j.jfma.2024.01.031_bib43 article-title: Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma publication-title: PLoS One doi: 10.1371/journal.pone.0231828 – volume: 19 start-page: 329 year: 1999 ident: 10.1016/j.jfma.2024.01.031_bib2 article-title: Prognosis of hepatocellular carcinoma: the BCLC staging classification publication-title: Semin Liver Dis doi: 10.1055/s-2007-1007122 – volume: 8 start-page: 299 year: 2019 ident: 10.1016/j.jfma.2024.01.031_bib24 article-title: A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE publication-title: Liver Cancer doi: 10.1159/000502905 – volume: 57 start-page: 2358 year: 2013 ident: 10.1016/j.jfma.2024.01.031_bib34 article-title: Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells publication-title: Hepatology doi: 10.1002/hep.26328 – volume: 134 start-page: 319 year: 2014 ident: 10.1016/j.jfma.2024.01.031_bib38 article-title: Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity publication-title: Int J Cancer doi: 10.1002/ijc.28362 – volume: 62 start-page: 737 year: 2013 ident: 10.1016/j.jfma.2024.01.031_bib40 article-title: Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-012-1380-8 – volume: 38 start-page: 2960 year: 2020 ident: 10.1016/j.jfma.2024.01.031_bib23 article-title: Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma publication-title: J Clin Oncol doi: 10.1200/JCO.20.00808 – volume: 33 start-page: 550 year: 2015 ident: 10.1016/j.jfma.2024.01.031_bib31 article-title: Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade publication-title: J Clin Oncol doi: 10.1200/JCO.2014.57.9151 – volume: 74 start-page: 68 year: 2014 ident: 10.1016/j.jfma.2024.01.031_bib36 article-title: Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Ralpha and NKG2D triggering publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-1186 – volume: 16 start-page: 859 year: 2015 ident: 10.1016/j.jfma.2024.01.031_bib11 article-title: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)00050-9 – volume: 389 start-page: 2492 year: 2017 ident: 10.1016/j.jfma.2024.01.031_bib8 article-title: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial publication-title: Lancet doi: 10.1016/S0140-6736(17)31046-2 – volume: 69 start-page: 1492 year: 2020 ident: 10.1016/j.jfma.2024.01.031_bib13 article-title: Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial publication-title: Gut doi: 10.1136/gutjnl-2019-318934 – volume: 66 start-page: 545 year: 2017 ident: 10.1016/j.jfma.2024.01.031_bib17 article-title: Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2016.10.029 – volume: 69 start-page: 353 year: 2018 ident: 10.1016/j.jfma.2024.01.031_bib10 article-title: Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial publication-title: J Hepatol doi: 10.1016/j.jhep.2018.04.010 – volume: 39 start-page: 5149 year: 2019 ident: 10.1016/j.jfma.2024.01.031_bib42 article-title: Impact of relative dose intensity of early-phase lenvatinib treatment on therapeutic response in hepatocellular carcinoma publication-title: Anticancer Res doi: 10.21873/anticanres.13710 – volume: 9 start-page: 756 year: 2020 ident: 10.1016/j.jfma.2024.01.031_bib18 article-title: Lenvatinib-transarterial chemoembolization sequential therapy as an effective treatment at progression during lenvatinib therapy for advanced hepatocellular carcinoma publication-title: Liver Cancer doi: 10.1159/000510299 – volume: 39 start-page: 5695 year: 2019 ident: 10.1016/j.jfma.2024.01.031_bib25 article-title: Conversion hepatectomy for huge hepatocellular carcinoma with arterioportal shunt after chemoembolization and lenvatinib therapy publication-title: Anticancer Res doi: 10.21873/anticanres.13768 – volume: 14 start-page: 849 year: 2014 ident: 10.1016/j.jfma.2024.01.031_bib28 article-title: Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma publication-title: BMC Cancer doi: 10.1186/1471-2407-14-849 – volume: 6 start-page: 204 year: 2017 ident: 10.1016/j.jfma.2024.01.031_bib32 article-title: Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan society of hepatology: a comparison with the liver damage and child-pugh classifications publication-title: Liver Cancer doi: 10.1159/000452846 – volume: 69 start-page: 182 year: 2018 ident: 10.1016/j.jfma.2024.01.031_bib21 article-title: Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma publication-title: J Hepatol doi: 10.1016/j.jhep.2018.03.019 – volume: 20 start-page: 282 year: 2019 ident: 10.1016/j.jfma.2024.01.031_bib7 article-title: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30937-9 – volume: 379 start-page: 54 year: 2018 ident: 10.1016/j.jfma.2024.01.031_bib12 article-title: Cabozantinib in patients with advanced and progressing hepatocellular carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1717002 – volume: 8 start-page: 3506 year: 2017 ident: 10.1016/j.jfma.2024.01.031_bib27 article-title: Comparison of combined transcatheter arterial chemoembolization and CT-guided radiofrequency ablation with surgical resection in patients with hepatocellular carcinoma within the up-to-seven criteria: a multicenter case-matched study publication-title: J Cancer doi: 10.7150/jca.19964 – volume: 91 start-page: 598 year: 2011 ident: 10.1016/j.jfma.2024.01.031_bib39 article-title: Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model publication-title: Lab Invest doi: 10.1038/labinvest.2010.205 – volume: 120 start-page: 1051 year: 2021 ident: 10.1016/j.jfma.2024.01.031_bib20 article-title: Diagnosis G, systemic therapy G. Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the taiwan liver cancer association and the gastroenterological society of Taiwan publication-title: J Formos Med Assoc doi: 10.1016/j.jfma.2020.10.031 – volume: 2 start-page: 1090 year: 2014 ident: 10.1016/j.jfma.2024.01.031_bib35 article-title: Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-14-0076 – volume: 38 start-page: 193 year: 2020 ident: 10.1016/j.jfma.2024.01.031_bib6 article-title: Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial publication-title: J Clin Oncol doi: 10.1200/JCO.19.01307 – volume: 11 start-page: 199 year: 2017 ident: 10.1016/j.jfma.2024.01.031_bib3 article-title: HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma publication-title: Hepatol Int doi: 10.1007/s12072-016-9774-x – volume: 13 year: 2021 ident: 10.1016/j.jfma.2024.01.031_bib19 article-title: Alternating lenvatinib and trans-arterial therapy prolongs overall survival in patients with inter-mediate stage HepatoCellular carcinoma: a propensity score matching study publication-title: Cancers doi: 10.3390/cancers13010160 – volume: 6 start-page: 318 year: 2020 ident: 10.1016/j.jfma.2024.01.031_bib26 article-title: Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy publication-title: Surg Case Rep doi: 10.1186/s40792-020-01078-3 – volume: 391 start-page: 1163 year: 2018 ident: 10.1016/j.jfma.2024.01.031_bib5 article-title: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial publication-title: Lancet doi: 10.1016/S0140-6736(18)30207-1 – volume: 382 start-page: 1894 year: 2020 ident: 10.1016/j.jfma.2024.01.031_bib9 article-title: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1915745 – volume: 31 start-page: 426 year: 2013 ident: 10.1016/j.jfma.2024.01.031_bib29 article-title: Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial publication-title: J Clin Oncol doi: 10.1200/JCO.2012.42.9936 – volume: 142 start-page: 1878 year: 2018 ident: 10.1016/j.jfma.2024.01.031_bib41 article-title: Targeting tumor-infiltrating Ly6G(+) myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma publication-title: Int J Cancer doi: 10.1002/ijc.31216 – volume: 97 start-page: 277 year: 2019 ident: 10.1016/j.jfma.2024.01.031_bib30 article-title: Important clinical factors in sequential therapy including lenvatinib against unresectable hepatocellular carcinoma publication-title: Oncology doi: 10.1159/000501281 – volume: 46 start-page: 112 year: 2017 ident: 10.1016/j.jfma.2024.01.031_bib37 article-title: Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo publication-title: Int Immunopharm doi: 10.1016/j.intimp.2017.02.028 – volume: 381 start-page: e2 year: 2019 ident: 10.1016/j.jfma.2024.01.031_bib1 article-title: Hepatocellular carcinoma publication-title: Reply. N Engl J Med – volume: 2 start-page: 565 year: 2017 ident: 10.1016/j.jfma.2024.01.031_bib16 article-title: Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial publication-title: Lancet Gastroenterol Hepatol doi: 10.1016/S2468-1253(17)30156-5 – volume: 70 start-page: 684 year: 2019 ident: 10.1016/j.jfma.2024.01.031_bib14 article-title: Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial publication-title: J Hepatol doi: 10.1016/j.jhep.2018.11.029 – volume: 55 start-page: 1309 year: 2011 ident: 10.1016/j.jfma.2024.01.031_bib22 article-title: EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization publication-title: J Hepatol doi: 10.1016/j.jhep.2011.03.007 |
| SSID | ssj0046996 |
| Score | 2.3627274 |
| Snippet | Locoregional therapy and multi-kinase inhibitor agent have been the backbone of treatment for hepatocellular carcinoma (HCC) patients. However, the effect of... Background: Locoregional therapy and multi-kinase inhibitor agent have been the backbone of treatment for hepatocellular carcinoma (HCC) patients. However, the... |
| SourceID | doaj proquest pubmed crossref elsevier |
| SourceType | Open Website Aggregation Database Index Database Publisher |
| StartPage | 788 |
| SubjectTerms | Lenvatinib Radiofrequency ablation Survival Systemic therapy Transarterial chemoembolization |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iQbyIb9cXEbxJsW2SbnNUUUTQk4K3kDSJrmgru13Bg__dmaRd9KBevJRS2ibtTGe-Sb-ZIeTQ6MoPeeETx9gw4VyWSSly0GUpLePgL6THBOfrm-Lyjl_di_svrb6QExbLA8cXd2xt6kpuBcRxnheOy1znGctgZC40DynkeSrTPpiKNhhivtCZK5VI7ih40aXLRGbXkw8Vh3IeCnay7JtLCpX7v3mmn5Bn8EAXy2Spg470JE55hcy5epUsXHc_x9fIBxqBwIxuKbioBnsuIM6mMcfqncIIz039MKGTKRgIUDE6qmkgaCEX9s3RR_BNbYNr-UhOpRX2GaqbF0276qsTiilnYwqeCldy65GhM6L6Orm7OL89u0y67gpJxYuyTbTxAgGVlbDnsOwLBMq2shwiJDCAmllXGcG8Lz3XxjKXO4h9fDbUJnOwZRtkvm5qt0VoKrXQBoIby_AvptAOgkRphBNVXrBKDMhR_4LVayyioXp22ZNCcSgUh0ozBeIYkFOUwexMLIAdDoBaqE4t1F9qMSCsl6Dqc0zBKsKNRr8OLWZXdQgkIos_rzvolUTB54ly0rVrphOVgwbCvACXDshm1J7ZgzFs8gYQb_s_HniHLOKEIpN4l8y346nbA7zUmv3waXwCAf8TEA priority: 102 providerName: Directory of Open Access Journals |
| Title | Subsequent locoregional therapy prolongs survival in progressive hepatocellular carcinoma patients under lenvatinib treatment |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0929664624000846 https://dx.doi.org/10.1016/j.jfma.2024.01.031 https://www.ncbi.nlm.nih.gov/pubmed/38310071 https://www.proquest.com/docview/2929131551 https://doaj.org/article/dd0e84d5046f46e492a2131ecc45a421 |
| Volume | 123 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9wwELXQHhAXRCkfSwtypd6qsElsZ5NjQUWrSvTSInGz7NhesoIE7WaRONDf3hnHibQHisQl2kROnM1M5s04b2YI-apV6aY8c5FlbBpxXuRRLlLQ5aIwjANeFA4TnK9_ZbMb_vNW3G6Ryz4XBmmVwfZ3Nt1b63BkEp7m5LGqJr9jQPYs4xmyIGOAUcxg51PU9fO_A80Doj_fowsHRzg6JM50HK-F87WHUu5Ld7JkA5x8Df8NjHrNB_VYdLVHdoMTSb939_mBbNl6n2xfh8_kH8kLmgPPkW4pgFWD3RfQ46ZdttUzhRnum3q-oqs1mApQNlrV1FO1kBX7ZOkdoFTb4Ko-0lRpiR2H6uZB0VCHdUUx-WxJAbNwTbeuNB0o6wfk5urHn8tZFPosRCXP8jZS2gl0rUwBvywWgIGQ2ZSGQ6wEplAxY0stmHO540obZlMLUZBLpkonFrbskIzqprbHhMaFEkpDmGMYfs8UykK4WGhhRZlmrBRj8q1_wPKxK6che57ZQqI4JIpDxokEcYzJBcpgGImlsP2BZjmXQRekMbHNuREgasczy4tUpQlLQDW5UDyFi7BegrLPNgX7CBeq_ju1GM7a0Mc3z_vSK4mEFxXlpGrbrFcyBQ2E-wIPdUyOOu0Z_hjDdm_g7J28c9ZPZAf3OhrxZzJql2t7Cs5Sq8_823Dmlxr-ARs6FLk |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIgEXxJvlaSRuKGwS29nkCBXVAt1eaKXeLDu221SQVLtZJA7w25lxnEh7ACQuUZQ4cZL5Mo_kmxmA10bXfiEKnzjOF4kQVZmUMkcsV5XlAu1F5SnBeXVcLE_FpzN5tgcHYy4M0Sqj7h90etDWccs8Ps35VdPMv6Ro2YtCFMSCTNGMXoPrgtocIKjf_pp4Hhj-hSZdNDqh4TFzZiB5XfpQfCgXoXYnz3asUyjiv2Ok_uSEBmN0eAduRy-SvRsu9C7sufYe3FjF_-T34Sfpg0CS7hlaq47aL5DLzYZ0qx8MZ_jatecbttmirkC0saZlgatFtNjvjl2gmeo7-qxPPFVWU8uhtvumWSzEumGUfbZmaLToo27bGDZx1h_A6eGHk4NlEhstJLUoyj7RxkvyrWyFa44qwGDMbGsrMFhCXai5dbWR3PvSC20sd7nDMMhnC20yh0v-EPbbrnWPgaWVltpgnGM5_dCU2mG8WBnpZJ0XvJYzeDM-YHU11NNQI9HsUpE4FIlDpZlCcczgPclgGkm1sMOGbn2uIhiUtakrhZUoai8KJ6pc5xnPEJtCapHjSfgoQTWmm6KCxBM1f51aTkftAPKfx70aQaLwTSU56dZ1243KEYF4XeiizuDRgJ7pxjj1e0Nv78l_zvoSbi5PVkfq6OPx56dwi_YMnOJnsN-vt-45ek69eRHejN9gnRbb |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Subsequent+locoregional+therapy+prolongs+survival+in+progressive+hepatocellular+carcinoma+patients+under+lenvatinib+treatment&rft.jtitle=Journal+of+the+Formosan+Medical+Association&rft.au=Lin%2C+Po-Ting&rft.au=Teng%2C+Wei&rft.au=Jeng%2C+Wen-Juei&rft.au=Lin%2C+Chen-Chun&rft.date=2024-07-01&rft.pub=Elsevier+B.V&rft.issn=0929-6646&rft.eissn=1876-0821&rft.volume=123&rft.issue=7&rft.spage=788&rft.epage=795&rft_id=info:doi/10.1016%2Fj.jfma.2024.01.031&rft.externalDocID=S0929664624000846 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0929-6646&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0929-6646&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0929-6646&client=summon |